Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1646 1674
This examiner grants 60% of resolved cases
Ruixiang Li is an examiner in Tech Center 1600 and Art Unit 1634. He has 1029 resolved cases. The allowance rate for these cases is 59.5 percent. This percentage represents the frequency of patent grants among his resolved matters. The interview lift is 18.6 percent. This metric measures the increase in the probability of allowance following an examiner interview. The median time to allowance is 1017 days.
With 1029 resolved cases, the 59.5 percent allowance rate offers a clear view of the examiner's tendencies. The 18.6 percent interview lift indicates that direct communication is an effective strategy for applicants. The 1017 days median time to allowance is a key figure for planning the lifecycle of an application. These statistics help practitioners navigate the specific requirements of Art Unit 1634. The allowance rate and interview lift are the primary indicators of success in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18249807 | PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES | Non-Final OA | Janssen Biotech, Inc. |
| 19080346 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | Final Rejection | TRUSTEES OF BOSTON UNIVERSITY |
| 18670261 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Non-Final OA | AbbVie Inc. |
| 18359483 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17924612 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18400667 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Non-Final OA | Washington University |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18668446 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | Non-Final OA | SANOFI BIOTECHNOLOGY |
| 18038460 | INHIBITOR OF FIBROSIS PROGRESSION | Non-Final OA | The University of Tokyo |
| 18037702 | MONITORING MEMBRANE PROTEIN TRAFFICKING FOR DRUG DISCOVERY AND DRUG DEVELOPMENT | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18621483 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER | Non-Final OA | ASTRAZENECA AB |
| 18506571 | MONOCLONAL IGM ANTIBODIES FROM ENTIRELY CARBOHYDRATE CONSTRUCTS | Non-Final OA | The University of Toledo |
| 17441849 | PHOTOACTIVE ANTIBODIES | Final Rejection | UEA ENTERPRISES LIMITED |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | Final Rejection | BioNTech SE |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | Non-Final OA | Omeros Corporation |
| 18449460 | ERBB-2 AND ERBB3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | Non-Final OA | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy